KRAS and neoplasm: Immunoblot analyses of SETD8 and its histone and non-histone targets on xenograft tumor tissues-derived proteins indicated that SGSS05-NS3 treatment reduced H4K20me1 and p53K382me1 levels (Fig. 5I-K).